Subhash Chander
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Subhash Chander has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Om Parkash
Department of Medicine, Montefiore Medical Center Wakefield, Bronx, NY
10 shared publicationsRoopa Kumari
Department of Surgical Pathology, Mayo Clinic, Rochester, MN
10 shared publicationsFnu Sadarat
Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
8 shared publicationsSindhu Luhana
Aga Khan University Hospital
6 shared publicationsAbhi Chand Lohana
4 shared publications- Abhi Chand Lohana
Department of Internal Medicine, WVU Camden Clark Medical Center, Parkersburg, WV 26101, USA
4 shared publications
Latest Publications
- 28 August 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Osteoporosis and its clinical burden in chronic obstructive pulmonary disease: A retrospective cohort study
- 28 August 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Osteoporosis and its clinical burden in chronic obstructive pulmonary disease: A retrospective cohort study
- Open Access
- 18 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5650
Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study
Background/Objectives: Fixed-dose triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) at high risk of exacerbations; however, direct comparative effectiveness data between available triple therapy regimens remain limited. We compared real-world clinical outcomes among adults with COPD receiving fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR). Methods: We conducted a retrospective propensity score-matched cohort study using the TriNetX Research Network. Adults with a spirometrically confirmed diagnosis of COPD who received fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR) between July 2020 and August 2024 were included in the analysis. A 365-day landmark period was applied to establish maintenance therapy, with outcome follow-up beginning 1 year after treatment initiation. Patients were followed for outcomes through August 2025, the date of database analysis. After 1:1 propensity score matching, treatment groups were compared for COPD exacerbations, acute respiratory failure (ARF), hospitalization, and all-cause mortality using RR and Cox proportional hazards analyses. Results: In matched cohorts, FF/VI/UMEC was associated with a significantly higher risk of COPD exacerbations (5.6% vs. 3.9%; RR 1.44; 95% CI 1.30–1.59; p < 0.001) and ARF (2.5% vs. 1.9%; RR 1.28; 95% CI 1.11–1.46; p < 0.001) compared with BUD/GLY/FOR. Time-to-event analyses demonstrated lower event-free probability for exacerbations (HR 1.35; (95% CI 1.21–1.50) and ARF (HR 1.15; (95% CI 1.00–1.32))). All-cause mortality was numerically higher in the FF/VI/UMEC cohort (5.2% vs. 4.7%; RR 1.09; 95% CI 1.00–1.19; p = 0.050); however, time-to-event analysis did not demonstrate a statistically significant difference. Hospitalization rates were similar between groups. Conclusions: In this large propensity score-matched real-world cohort study, patients receiving BUD/GLY/FOR experienced lower rates of COPD exacerbations and acute respiratory failure than those receiving FF/VI/UMEC. Because of the retrospective observational nature of the analysis, these findings should be considered hypothesis-generating and require confirmation in prospective comparative effectiveness studies.
- 18 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5650
Open AccessComparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study
Background/Objectives: Fixed-dose triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) at high risk of exacerbations; however, direct comparative effectiveness data between available triple therapy regimens remain limited. We compared real-world clinical outcomes among adults with COPD receiving fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR). Methods: We conducted a retrospective propensity score-matched cohort study using the TriNetX Research Network. Adults with a spirometrically confirmed diagnosis of COPD who received fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR) between July 2020 and August 2024 were included in the analysis. A 365-day landmark period was applied to establish maintenance therapy, with outcome follow-up beginning 1 year after treatment initiation. Patients were followed for outcomes through August 2025, the date of database analysis. After 1:1 propensity score matching, treatment groups were compared for COPD exacerbations, acute respiratory failure (ARF), hospitalization, and all-cause mortality using RR and Cox proportional hazards analyses. Results: In matched cohorts, FF/VI/UMEC was associated with a significantly higher risk of COPD exacerbations (5.6% vs. 3.9%; RR 1.44; 95% CI 1.30–1.59; p < 0.001) and ARF (2.5% vs. 1.9%; RR 1.28; 95% CI 1.11–1.46; p < 0.001) compared with BUD/GLY/FOR. Time-to-event analyses demonstrated lower event-free probability for exacerbations (HR 1.35; (95% CI 1.21–1.50) and ARF (HR 1.15; (95% CI 1.00–1.32))). All-cause mortality was numerically higher in the FF/VI/UMEC cohort (5.2% vs. 4.7%; RR 1.09; 95% CI 1.00–1.19; p = 0.050); however, time-to-event analysis did not demonstrate a statistically significant difference. Hospitalization rates were similar between groups. Conclusions: In this large propensity score-matched real-world cohort study, patients receiving BUD/GLY/FOR experienced lower rates of COPD exacerbations and acute respiratory failure than those receiving FF/VI/UMEC. Because of the retrospective observational nature of the analysis, these findings should be considered hypothesis-generating and require confirmation in prospective comparative effectiveness studies.
- 18 December 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 251, 108599
Temporal trends in ICU outcomes by BMI: A retrospective propensity-score matched study
- 18 December 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 251, 108599
Temporal trends in ICU outcomes by BMI: A retrospective propensity-score matched study
- 5 August 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 247, 108291
The effect of kidney replacement therapy on lung mechanics and respiratory function: A systematic review and meta-analysis
- 5 August 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 247, 108291
The effect of kidney replacement therapy on lung mechanics and respiratory function: A systematic review and meta-analysis
- Open Access
- 21 July 2025
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 9 (4)
Nonsurgical Management of Abdominal Compartment Syndrome Using Transarterial Embolization and Percutaneous Catheter Drainage: A Case Report
- 21 July 2025
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 9 (4)
Open AccessNonsurgical Management of Abdominal Compartment Syndrome Using Transarterial Embolization and Percutaneous Catheter Drainage: A Case Report
- 9 April 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (5) , 913-916
Persistent Gender Gap in the Authorship of Hematology/Oncology Clinical Trials During the Past Two Decades
- 9 April 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (5) , 913-916
Persistent Gender Gap in the Authorship of Hematology/Oncology Clinical Trials During the Past Two Decades
- 3 March 2025
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 56 (5) , 555-570
Clinical Outcomes of Patients undergoing Hemodialysis with Cool versus Standard Dialysate: A Systematic Review and Meta-Analysis
Introduction: Clinical practice guidelines recommend lower (35.0°C–35.5°C) instead of standard dialysate temperature (36.5°C–37.0°C) to mitigate the risk of intradialytic hypotension. However, many studies have been available since the recommendations were published. Hence, the current study aimed to provide an updated meta-analysis of clinical outcomes with cold versus standard dialysate. Methods: This systematic review and meta-analysis included eligible articles indexed in PubMed, Cochrane Library, Web of Science, and Scopus, evaluating the effects of cooled versus standard dialysate in hemodialysis patients. The primary outcomes were intradialytic hypotension, mean arterial pressure, thermal-related discomfort, and body temperature changes. A random-effects model was used for all outcomes due to high heterogeneity (I2: intradialytic hypotension = 60%, mean arterial pressure = 72%, symptoms of discomfort = 41%, decrease in body temperature = 87%). Sensitivity analysis was performed using the “leave-one-out” approach, and the Cochrane risk-of-bias tool was used to assess study quality. A total of 31 studies were included. Pooled results indicate that cooled dialysis was associated with a lower risk of intradialytic hypotension (RR 0.67; 95% CI: 0.48–0.93; p = 0.02) and higher mean arterial pressure (MD 7.18; 95% CI: 3.79–10.58; p < 0.01). However, cooled dialysis was associated with a higher risk of discomfort (RR 1.55; 95% CI: 1.25–1.93; p < 0.01) and a significant decrease in body temperature (MD −0.29; 95% CI: −0.52 to −0.05; p = 0.02). This systematic review and meta-analysis is registered in PROSPERO under ID CRD42024589307. Conclusions: Using cooled dialysate might be a simple approach to reduce interdialytic hypotension risk and increase mean arterial pressure, albeit at the cost of patient discomfort. The limitations associated with the quality of included studies underscore the need for high-quality, multicenter studies with large/diverse study populations.
- 3 March 2025
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 56 (5) , 555-570
Clinical Outcomes of Patients undergoing Hemodialysis with Cool versus Standard Dialysate: A Systematic Review and Meta-Analysis
Introduction: Clinical practice guidelines recommend lower (35.0°C–35.5°C) instead of standard dialysate temperature (36.5°C–37.0°C) to mitigate the risk of intradialytic hypotension. However, many studies have been available since the recommendations were published. Hence, the current study aimed to provide an updated meta-analysis of clinical outcomes with cold versus standard dialysate. Methods: This systematic review and meta-analysis included eligible articles indexed in PubMed, Cochrane Library, Web of Science, and Scopus, evaluating the effects of cooled versus standard dialysate in hemodialysis patients. The primary outcomes were intradialytic hypotension, mean arterial pressure, thermal-related discomfort, and body temperature changes. A random-effects model was used for all outcomes due to high heterogeneity (I2: intradialytic hypotension = 60%, mean arterial pressure = 72%, symptoms of discomfort = 41%, decrease in body temperature = 87%). Sensitivity analysis was performed using the “leave-one-out” approach, and the Cochrane risk-of-bias tool was used to assess study quality. A total of 31 studies were included. Pooled results indicate that cooled dialysis was associated with a lower risk of intradialytic hypotension (RR 0.67; 95% CI: 0.48–0.93; p = 0.02) and higher mean arterial pressure (MD 7.18; 95% CI: 3.79–10.58; p < 0.01). However, cooled dialysis was associated with a higher risk of discomfort (RR 1.55; 95% CI: 1.25–1.93; p < 0.01) and a significant decrease in body temperature (MD −0.29; 95% CI: −0.52 to −0.05; p = 0.02). This systematic review and meta-analysis is registered in PROSPERO under ID CRD42024589307. Conclusions: Using cooled dialysate might be a simple approach to reduce interdialytic hypotension risk and increase mean arterial pressure, albeit at the cost of patient discomfort. The limitations associated with the quality of included studies underscore the need for high-quality, multicenter studies with large/diverse study populations.
- Open Access
- 13 January 2025
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 77 (1) , 1-11
Type of arrhythmias and the risk of sudden cardiac death in dialysis patients: a systematic review and meta-analysis
Background: Patients on long-term dialysis for end-stage kidney disease have a high mortality rate, predominantly due to sudden cardiac death (SCD), which is associated with an increased risk of arrhythmias compared to the general population. Thus, the current systematic review and meta-analysis aimed to investigate the incidence of SCD among dialysis patients at risk of arrhythmia. Methods: This systematic review and meta-analysis followed the PRISMA guidelines. PubMed, Cochrane Library, Google Scholar, Medline, and Europe PMC were searched for articles meeting our inclusion criteria. Studies with risk assessment of arrhythmias and the incidence of SCD in dialysis patients were considered for inclusion. Effect size from eligible studies was pooled using a random effects model and restricted maximum likelihood estimation. Heterogeneity was quantified using the I 2 statistic, and the risk of publication bias was evaluated by visually inspecting funnel plots. Results: Our search strategy yielded 5861 studies, of which 1960 duplicate entries were removed in the prescreening stage, 3326 were excluded after title/abstract screening, and 519 after full-text screening for not meeting our inclusion criteria. Finally, 11 studies were included in the analysis, and two more were selected from the bibliography list of previous reviews. Eight included studies were randomized controlled trials, and five were cohort studies, which provided a pooled population size of 12,611 dialysis patients for the meta-analysis, which indicated a significantly larger effect size of arrhythmia [Cohen’s d = 110.38 (95%CI 42.72–178.05), p = 0.0]. Visual assessment of the funnel plot indicated no publication bias. Conclusion: SCD remains a significant public health concern, particularly in patients undergoing dialysis. Meta-analysis results show that bradyarrhythmia is a common arrhythmic condition leading to SCD; however, other arrhythmias should also be considered.
- 13 January 2025
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 77 (1) , 1-11
Open AccessType of arrhythmias and the risk of sudden cardiac death in dialysis patients: a systematic review and meta-analysis
Background: Patients on long-term dialysis for end-stage kidney disease have a high mortality rate, predominantly due to sudden cardiac death (SCD), which is associated with an increased risk of arrhythmias compared to the general population. Thus, the current systematic review and meta-analysis aimed to investigate the incidence of SCD among dialysis patients at risk of arrhythmia. Methods: This systematic review and meta-analysis followed the PRISMA guidelines. PubMed, Cochrane Library, Google Scholar, Medline, and Europe PMC were searched for articles meeting our inclusion criteria. Studies with risk assessment of arrhythmias and the incidence of SCD in dialysis patients were considered for inclusion. Effect size from eligible studies was pooled using a random effects model and restricted maximum likelihood estimation. Heterogeneity was quantified using the I 2 statistic, and the risk of publication bias was evaluated by visually inspecting funnel plots. Results: Our search strategy yielded 5861 studies, of which 1960 duplicate entries were removed in the prescreening stage, 3326 were excluded after title/abstract screening, and 519 after full-text screening for not meeting our inclusion criteria. Finally, 11 studies were included in the analysis, and two more were selected from the bibliography list of previous reviews. Eight included studies were randomized controlled trials, and five were cohort studies, which provided a pooled population size of 12,611 dialysis patients for the meta-analysis, which indicated a significantly larger effect size of arrhythmia [Cohen’s d = 110.38 (95%CI 42.72–178.05), p = 0.0]. Visual assessment of the funnel plot indicated no publication bias. Conclusion: SCD remains a significant public health concern, particularly in patients undergoing dialysis. Meta-analysis results show that bradyarrhythmia is a common arrhythmic condition leading to SCD; however, other arrhythmias should also be considered.
- 19 December 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 56 (1) , 34
Gender, Race, and Regional Disparities in Leading Authorships of Gastroenterology and Hepatology Randomized Controlled Trials
Background and Aims To investigate gender, racial, ethnic, and regional disparities in first and senior authorship positions in gastroenterology/hepatology-related randomised controlled trials (RCT). Method Retrospective bibliometric analysis of PubMed-indexed RCTs published between January 2000 to December 2022 in leading journals with an impact factor of at least five. Results 943 RCTs met our inclusion criteria, providing a participant pool of 301 female (15.96%) and 1,585 male (84.04%) authors from 37 countries (70% high-income countries). Despite a significant increase in the proportion of female authors in first and senior authorship positions between 2000 and 2022 (p<0.001), females were grossly underrepresented in both authorship positions, with a male-to-female ratio of 4.45 and 6.37, respectively. The male-to-female ratio was highest among Asian authors (7.79) than among White (4.22), Hispanic (1.44), and Black (1) authors in the first authorship position. In contrast, the male-to-female ratio was similar for Asian (6.2) and White (6.67) authors in the senior authorship position, with a low underlying frequency of Hispanic and Black female authors. Conclusion Despite significant improvements in gender, racial and ethnic representation in first and senior authorship of gastroenterology/hepatology-related RCTs published in high-impact journals, progress toward parity remains slow. Targeted interventions to improve author diversity are warranted.
- 19 December 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 56 (1) , 34
Gender, Race, and Regional Disparities in Leading Authorships of Gastroenterology and Hepatology Randomized Controlled Trials
Background and Aims To investigate gender, racial, ethnic, and regional disparities in first and senior authorship positions in gastroenterology/hepatology-related randomised controlled trials (RCT). Method Retrospective bibliometric analysis of PubMed-indexed RCTs published between January 2000 to December 2022 in leading journals with an impact factor of at least five. Results 943 RCTs met our inclusion criteria, providing a participant pool of 301 female (15.96%) and 1,585 male (84.04%) authors from 37 countries (70% high-income countries). Despite a significant increase in the proportion of female authors in first and senior authorship positions between 2000 and 2022 (p<0.001), females were grossly underrepresented in both authorship positions, with a male-to-female ratio of 4.45 and 6.37, respectively. The male-to-female ratio was highest among Asian authors (7.79) than among White (4.22), Hispanic (1.44), and Black (1) authors in the first authorship position. In contrast, the male-to-female ratio was similar for Asian (6.2) and White (6.67) authors in the senior authorship position, with a low underlying frequency of Hispanic and Black female authors. Conclusion Despite significant improvements in gender, racial and ethnic representation in first and senior authorship of gastroenterology/hepatology-related RCTs published in high-impact journals, progress toward parity remains slow. Targeted interventions to improve author diversity are warranted.
- 2 October 2024
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 85 (3) , 303-319
Urea to Treat Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Systematic Review and Meta-Analysis
- 2 October 2024
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 85 (3) , 303-319
Urea to Treat Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Systematic Review and Meta-Analysis